Literature DB >> 27052162

Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression.

Yuliya V Katlinskaya1, Kanstantsin V Katlinski1, Qiujing Yu1, Angelica Ortiz1, Daniel P Beiting2, Angela Brice2, Diwakar Davar3, Cindy Sanders3, John M Kirkwood3, Hallgeir Rui4, Xiaowei Xu5, Constantinos Koumenis6, J Alan Diehl7, Serge Y Fuchs8.   

Abstract

Oncogene activation induces DNA damage responses and cell senescence. We report a key role of type I interferons (IFNs) in oncogene-induced senescence. IFN signaling-deficient melanocytes expressing activated Braf do not exhibit senescence and develop aggressive melanomas. Restoration of IFN signaling in IFN-deficient melanoma cells induces senescence and suppresses melanoma progression. Additional data from human melanoma patients and mouse transplanted tumor models suggest the importance of non-cell-autonomous IFN signaling. Inactivation of the IFN pathway is mediated by the IFN receptor IFNAR1 downregulation that invariably occurs during melanoma development. Mice harboring an IFNAR1 mutant, which is partially resistant to downregulation, delay melanoma development, suppress metastatic disease, and better respond to BRAF or PD-1 inhibitors. These results suggest that IFN signaling is an important tumor-suppressive pathway that inhibits melanoma development and progression and argue for targeting IFNAR1 downregulation to prevent metastatic disease and improve the efficacy of molecularly target and immune-targeted melanoma therapies.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BRAF; interferon receptor; melanoma; metastasis; senescence; type I interferon

Mesh:

Substances:

Year:  2016        PMID: 27052162      PMCID: PMC4826807          DOI: 10.1016/j.celrep.2016.03.006

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  56 in total

Review 1.  Cutaneous melanoma in the era of molecular profiling.

Authors:  John F Thompson; Richard A Scolyer; Richard F Kefford
Journal:  Lancet       Date:  2009-08-01       Impact factor: 79.321

2.  Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.

Authors:  Stefani Spranger; Riyue Bao; Thomas F Gajewski
Journal:  Nature       Date:  2015-05-11       Impact factor: 49.962

3.  Raf inhibitor stabilizes receptor for the type I interferon but inhibits its anti-proliferative effects in human malignant melanoma cells.

Authors:  K G Suresh Kumar; Jianghuai Liu; Ying Li; Duonan Yu; Andrei Thomas-Tikhonenko; Meenhard Herlyn; Serge Y Fuchs
Journal:  Cancer Biol Ther       Date:  2007-06-13       Impact factor: 4.742

4.  Inducible priming phosphorylation promotes ligand-independent degradation of the IFNAR1 chain of type I interferon receptor.

Authors:  Sabyasachi Bhattacharya; Wei-Chun HuangFu; Jianghuai Liu; Sudhakar Veeranki; Darren P Baker; Constantinos Koumenis; J Alan Diehl; Serge Y Fuchs
Journal:  J Biol Chem       Date:  2009-11-30       Impact factor: 5.157

Review 5.  Predictors of response to interferon therapy.

Authors:  Helen Gogas; John M Kirkwood
Journal:  Curr Opin Oncol       Date:  2009-03       Impact factor: 3.645

6.  Impaired interferon signaling is a common immune defect in human cancer.

Authors:  Rebecca J Critchley-Thorne; Diana L Simons; Ning Yan; Andrea K Miyahira; Frederick M Dirbas; Denise L Johnson; Susan M Swetter; Robert W Carlson; George A Fisher; Albert Koong; Susan Holmes; Peter P Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-18       Impact factor: 11.205

7.  Virus-induced unfolded protein response attenuates antiviral defenses via phosphorylation-dependent degradation of the type I interferon receptor.

Authors:  Jianghuai Liu; Wei-Chun HuangFu; K G Suresh Kumar; Juan Qian; James P Casey; Robert B Hamanaka; Christina Grigoriadou; Rafael Aldabe; J Alan Diehl; Serge Y Fuchs
Journal:  Cell Host Microbe       Date:  2009-01-22       Impact factor: 21.023

8.  Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.

Authors:  David Dankort; David P Curley; Robert A Cartlidge; Betsy Nelson; Anthony N Karnezis; William E Damsky; Mingjian J You; Ronald A DePinho; Martin McMahon; Marcus Bosenberg
Journal:  Nat Genet       Date:  2009-03-12       Impact factor: 38.330

9.  Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7.

Authors:  Narendra Wajapeyee; Ryan W Serra; Xiaochun Zhu; Meera Mahalingam; Michael R Green
Journal:  Cell       Date:  2008-02-08       Impact factor: 41.582

Review 10.  Interferons at age 50: past, current and future impact on biomedicine.

Authors:  Ernest C Borden; Ganes C Sen; Gilles Uze; Robert H Silverman; Richard M Ransohoff; Graham R Foster; George R Stark
Journal:  Nat Rev Drug Discov       Date:  2007-12       Impact factor: 84.694

View more
  41 in total

1.  Pan-cancer transcriptomic analysis dissects immune and proliferative functions of APOBEC3 cytidine deaminases.

Authors:  Joseph C F Ng; Jelmar Quist; Anita Grigoriadis; Michael H Malim; Franca Fraternali
Journal:  Nucleic Acids Res       Date:  2019-02-20       Impact factor: 16.971

2.  Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment.

Authors:  Kanstantsin V Katlinski; Jun Gui; Yuliya V Katlinskaya; Angelíca Ortiz; Riddhita Chakraborty; Sabyasachi Bhattacharya; Christopher J Carbone; Daniel P Beiting; Melanie A Girondo; Amy R Peck; Ellen Puré; Priya Chatterji; Anil K Rustgi; J Alan Diehl; Constantinos Koumenis; Hallgeir Rui; Serge Y Fuchs
Journal:  Cancer Cell       Date:  2017-02-13       Impact factor: 31.743

3.  IFNAR1 Degradation: A New Mechanism for Tumor Immune Evasion?

Authors:  Romina E Araya; Romina S Goldszmid
Journal:  Cancer Cell       Date:  2017-02-13       Impact factor: 31.743

Review 4.  The molecular basis for differential type I interferon signaling.

Authors:  Gideon Schreiber
Journal:  J Biol Chem       Date:  2017-03-13       Impact factor: 5.157

5.  Expression of the IFNAR1 chain of type 1 interferon receptor in benign cells protects against progression of acute leukemia.

Authors:  Bin Zhao; Sabyasachi Bhattacharya; Qiujing Yu; Serge Y Fuchs
Journal:  Leuk Lymphoma       Date:  2017-05-15

6.  Regulation of intercellular biomolecule transfer-driven tumor angiogenesis and responses to anticancer therapies.

Authors:  Zhen Lu; Angelica Ortiz; Ioannis I Verginadis; Amy R Peck; Farima Zahedi; Christina Cho; Pengfei Yu; Rachel M DeRita; Hongru Zhang; Ryan Kubanoff; Yunguang Sun; Andrew T Yaspan; Elise Krespan; Daniel P Beiting; Enrico Radaelli; Sandra W Ryeom; J Alan Diehl; Hallgeir Rui; Constantinos Koumenis; Serge Y Fuchs
Journal:  J Clin Invest       Date:  2021-05-17       Impact factor: 14.808

Review 7.  Cellular senescence in ageing: from mechanisms to therapeutic opportunities.

Authors:  Raffaella Di Micco; Valery Krizhanovsky; Darren Baker; Fabrizio d'Adda di Fagagna
Journal:  Nat Rev Mol Cell Biol       Date:  2020-12-16       Impact factor: 94.444

8.  Loss of type I IFN responsiveness impairs natural killer cell antitumor activity in breast cancer.

Authors:  Damien J Zanker; Katie L Owen; Nikola Baschuk; Alex J Spurling; Belinda S Parker
Journal:  Cancer Immunol Immunother       Date:  2021-01-15       Impact factor: 6.968

9.  An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles.

Authors:  Angelica Ortiz; Jun Gui; Farima Zahedi; Pengfei Yu; Christina Cho; Sabyasachi Bhattacharya; Christopher J Carbone; Qiujing Yu; Kanstantsin V Katlinski; Yuliya V Katlinskaya; Simran Handa; Victor Haas; Susan W Volk; Angela K Brice; Kim Wals; Nicholas J Matheson; Robin Antrobus; Sonja Ludwig; Theresa L Whiteside; Cindy Sander; Ahmad A Tarhini; John M Kirkwood; Paul J Lehner; Wei Guo; Hallgeir Rui; Andy J Minn; Constantinos Koumenis; J Alan Diehl; Serge Y Fuchs
Journal:  Cancer Cell       Date:  2019-01-14       Impact factor: 31.743

10.  Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma.

Authors:  Diwakar Davar; Hong Wang; Joe-Marc Chauvin; Ornella Pagliano; Julien J Fourcade; Mignane Ka; Carmine Menna; Amy Rose; Cindy Sander; Amir A Borhani; Arivarasan Karunamurthy; Ahmad A Tarhini; Hussein A Tawbi; Qing Zhao; Blanca H Moreno; Scott Ebbinghaus; Nageatte Ibrahim; John M Kirkwood; Hassane M Zarour
Journal:  J Clin Oncol       Date:  2018-10-25       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.